高视医疗科技有限公司是一家主要从事眼科医疗器械及耗材的研发、制造及销售的投资控股公司。该公 司经营四个分部。自有产品分部开发及生产手术设备及相关配套软件、内光透镜、眼科疾病诊断及治疗 设备以及相关配套耗材。经销分部销售其他眼科医疗器械制造商生产的多功能诊断设备、眼底诊断、手 术及治疗设备以及相关配套耗材。技术服务分部提供保修服务、维护服务及售后服务所用耗材。其他分 部主要包括授出知识产权权限，以及提供临床研究组织相关服务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月5日南向资金减持2.32万股高视医疗（02407.HK）。近5个交易日中，获南向资金减 持的有5天，累计净减持4.29万股。近20个交易日中，获南向资金减持的有20天，累计净减持18.8万股。 截至目前，南向资金持有高视医疗（02407.HK）568.13万股，占公司已发行普通股的3.83%。 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 高视医疗科技有限公司 (於開曼群島註冊成立的有限責任公司) 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02407 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 | USD | ...

Core Viewpoint - The stock price of Gaoshi Medical (02407) has experienced fluctuations following its removal from the Hong Kong Stock Connect list, with a significant increase of 65.50% from May to September last year, but has since faced a decline of nearly 20% since December 22, raising questions about its upcoming performance in the 2025 annual report [1][2]. Group 1: Stock Performance - After being removed from the Hong Kong Stock Connect list, Gaoshi Medical's stock price initially rose, achieving a monthly "four consecutive increases" [1]. - The stock price saw a cumulative increase of 65.50% from May to September last year, but began a three-month period of sideways movement starting in mid-September [1]. - Since December 22, the stock has declined nearly 20%, effectively reversing all gains made since the mid-year report [1]. Group 2: Market Dynamics - On March 10, the adjustment of the Hong Kong Stock Connect list led to an average stock price drop of 14.24% for the excluded stocks, with Gaoshi Medical being one of them [1]. - Despite the stock's removal, the proportion of shares held by Hong Kong Stock Connect investors has only decreased by 3% over the past 10 months, indicating limited selling pressure [2]. - The liquidity of Gaoshi Medical's stock has noticeably decreased post-removal, with monthly trading volumes dropping by 84.39% from February to April last year [4]. Group 3: Financial Performance - In 2024, Gaoshi Medical reported revenues of 1.428 billion yuan, a year-on-year increase of 1.6%, but net profit fell by 46.75% to 92.394 million yuan due to factors like currency fluctuations and goodwill impairment [7]. - The company has been attempting to adjust its business structure by increasing the proportion of self-owned products, but the revenue from agency products rebounded to 68.55% in 2024 [8]. - In the first half of 2025, Gaoshi Medical achieved revenues of 653 million yuan, a 1.7% increase year-on-year, with a gross profit margin of 48.3%, reflecting an improvement [9]. Group 4: Future Outlook - Analysts project that Gaoshi Medical's revenues will grow to 1.564 billion, 1.715 billion, and 1.875 billion yuan from 2025 to 2027, with corresponding net profits of 135 million, 180 million, and 214 million yuan [9]. - Following the release of the mid-year report, Gaoshi Medical's stock price surged by 19.31% over two days, indicating positive market sentiment towards its performance [9]. - The current trading volume and price movements suggest that the stock may be nearing a bottom, with potential for recovery as market conditions improve [10].

不过，高视医疗的股价并未一路上攻，去年9月中下旬开始，随着港股医药板块的整体回调，高视医疗的股价也开始了一段为期3个月的横盘震荡，直到去年 12月下旬才跌破平台开始走低。 得益于2025年港股医药板块行情大涨以及公司中报亮眼表现，高视医疗(02407)在去年3月被踢出港股通名单后，股价反而实现了月度"四连阳"。去年5月至9 月，公司股价累涨幅度达到65.50%，在当时的"出通股"中表现亮眼。 智通财经APP观察到，从去年12月22日至今，高视医疗股价累计跌幅近20%，基本回吐了去年中报以来的所有涨幅。如今2025年报即将出炉，其能否凭借亮 眼业绩再获市场青睐? 港股通资金开启新一轮出清行情? 去年3月10日，2025第一期港股通标的的名单调整生效。当日，被剔除港股通的股票当日股价平均下跌14.24%，平均成交额上升19%。其中20只股票跌幅超 过10%，高视医疗便是其中之一。通常来说，标的"出通"后往往会迎来场内港股通资金的单向抛压，那高视医疗在去年12月下半月至今的这轮下跌行情，是 否是港股通资金开启的新一轮出清行情呢? 智通财经APP了解到，由于高视医疗在当时"出通"前的检讨周期内日平均市值仅为24.64 ...

Group 1 - The core point of the article is that southbound funds have reduced their holdings in Gaoshi Medical (02407.HK) by 900 shares on January 8, 2026, marking a trend of consistent reduction over recent trading days [1] - In the last 5 trading days, southbound funds have reduced their holdings for 5 days, with a total net reduction of 93,600 shares [1] - Over the past 20 trading days, there has been a total net reduction of 220,500 shares, indicating a sustained decrease in holdings [1] Group 2 - As of January 8, 2026, southbound funds hold 5.7582 million shares of Gaoshi Medical, which represents 3.88% of the company's total issued ordinary shares [1] - The shareholding changes over the last few trading days show a slight decline, with a maximum reduction of 72,200 shares on December 30, 2025, which corresponds to a 1.23% decrease [2] - Gaoshi Medical Technology Co., Ltd. is primarily engaged in the research, development, manufacturing, and sales of ophthalmic medical devices and consumables, operating through four segments [2]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 高视医疗科技有限公司 (於開曼群島註冊成立的有限責任公司) 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02407 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | 本月底法定/ ...

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Gaoshi Medical (02407.HK) by 2,800 shares on December 22, with a total net reduction of 30,700 shares over the last five trading days and 155,200 shares over the last twenty trading days [1] - As of now, southbound funds hold 5,852,700 shares of Gaoshi Medical, which represents 3.95% of the company's total issued ordinary shares [1] Group 2 - Gaoshi Medical Technology Co., Ltd. primarily engages in the research, development, manufacturing, and sales of ophthalmic medical devices and consumables [1] - The company operates through four segments: proprietary products, distribution, technical services, and others [1] - The proprietary products segment develops and produces surgical equipment and related software, intraocular lenses, diagnostic and treatment equipment for eye diseases, and related consumables [1] - The distribution segment sells multifunctional diagnostic equipment, fundus diagnostic, surgical, and treatment equipment produced by other ophthalmic medical device manufacturers, along with related consumables [1] - The technical services segment provides warranty services, maintenance services, and consumables used for after-sales services [1] - The other segment mainly includes granting intellectual property rights and providing clinical research organization-related services [1]

Group 1 - The core point of the news is that Southbound funds have reduced their holdings in Gaoshi Medical (02407.HK) by 2,900 shares on December 9, 2025, marking a continuous trend of reduction over the past trading days [1] - In the last 5 trading days, Southbound funds have cumulatively reduced their holdings by 70,500 shares, while in the last 20 trading days, the total reduction amounts to 151,000 shares [1] - As of now, Southbound funds hold 5,908,200 shares of Gaoshi Medical, which represents 3.99% of the company's total issued ordinary shares [1] Group 2 - Gaoshi Medical Technology Co., Ltd. is primarily engaged in the research, development, manufacturing, and sales of ophthalmic medical devices and consumables [2] - The company operates through four segments: proprietary products, distribution, technical services, and other services, including clinical research organization services [2] - The proprietary products segment develops and produces surgical equipment, related software, intraocular lenses, and diagnostic and treatment equipment for eye diseases [2]

高视医疗(02407)发布公告，公司附属公司深圳高视科技有限公司于近日正式获得由DEKRA签发的符合 ISO13485：2016/EN ISO13485：2016医疗器械质量管理体系认证证书(证书编号：4932952)。此次认证 全面覆盖了眼电生理诊断系统、角膜接触帽、超乳玻切手术系统集液盒的设计、开发、生产及销售全流 程。 DEKRA，成立于1925年，为一家全球领先的独立非上市专业检验检测认证机构，覆盖广阔的行业领 域。 ISO13485是国际标准化组织发布的医疗器械行业专用质量管理体系标准，聚焦"以患者为中心"的风险管 理与全流程质量控制，是全球医疗器械监管机构(如中国NMPA、欧盟CE、美国FDA等)认可的核心合规 性依据。通过该认证，意味着企业建立了覆盖设计开发、生产、检验、售后等产品全生命週期的质量管 理体系，确保产品符合法规要求并持续改进。 本次重要资质的获得，是公司在质量管理体系建设上的又一重要成果，为公司持续开拓国际市场奠定了 坚实基础。 ...

Core Viewpoint - The company, GaoShi Medical (02407), has received ISO 13485:2016/EN ISO 13485:2016 certification from DEKRA, indicating compliance with international quality management standards for medical devices [1] Group 1: Certification Details - The certification covers the entire process of design, development, production, and sales of the company's ophthalmic electrophysiological diagnostic systems, corneal contact caps, and phacoemulsification vitreous cutting surgical system collection boxes [1] - DEKRA, established in 1925, is a leading independent non-listed professional inspection, testing, and certification organization with a wide industry coverage [1] Group 2: Importance of ISO 13485 - ISO 13485 is a specialized quality management system standard for the medical device industry, focusing on patient-centered risk management and comprehensive quality control throughout the product lifecycle [1] - The certification is recognized by global medical device regulatory bodies such as China's NMPA, the EU's CE, and the US FDA, ensuring that products meet regulatory requirements and are subject to continuous improvement [1] Group 3: Strategic Implications - The acquisition of this important qualification represents a significant achievement in the company's quality management system development, laying a solid foundation for the company to expand into international markets [1]